Danaher's most recent trend suggests a bullish bias. One trading opportunity on Danaher is a Bull Put Spread using a strike $97.50 short put and a strike $92.50 long put offers a potential 14.94% return on risk over the next 27 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $97.50 by expiration. The full premium credit of $0.65 would be kept by the premium seller. The risk of $4.35 would be incurred if the stock dropped below the $92.50 long put strike price.
The 5-day moving average is moving up which suggests that the short-term momentum for Danaher is bullish and the probability of a rise in share price is higher if the stock starts trending.
The 20-day moving average is moving up which suggests that the medium-term momentum for Danaher is bullish.
The RSI indicator is above 80 which suggests that the stock is in overbought territory.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Danaher
See what the IHS Markit Score report has to say about Danaher Corp.
Thu, 18 Jan 2018 13:00:15 +0000
Danaher Corp NYSE:DHR
What’s the Potential Market for Accelerate Diagnostics’ Products?
Fri, 12 Jan 2018 15:50:02 +0000
How Is Accelerate Diagnostics Positioned at the Start of 2018? Accelerate Diagnostics’ (AXDX) Pheno System utilizes genotypic and phenotypic technology to identify infectious pathogens and perform antibiotic susceptibility tests (or AST), which determine if live bacterial or fungal cells are resistant or susceptible to a particular antimicrobial agent. The kit includes 140 assays for identification and susceptibility testing.
Danaher Sees RS Rating Rise To 74
Wed, 10 Jan 2018 08:00:00 +0000
Danaher shows rising price performance, earning an upgrade to its IBD Relative Strength Rating
Danaher Simply Blew It Away at This Big Healthcare Conference Tuesday
Tue, 09 Jan 2018 20:21:00 +0000
The CEO of the diversified machinery company says its core growth as well as earnings per share will top its guidance range when it releases the numbers at the end of the month.
Danaher CEO To Comment On Financial Performance
Tue, 09 Jan 2018 01:05:00 +0000
WASHINGTON, Jan. 8, 2018 /PRNewswire/ — Danaher Corporation (DHR) (the “Company”) announced that its President and Chief Executive Officer, Thomas P. Joyce, Jr., will comment tomorrow on the Company's fourth quarter 2017 performance in a presentation at the J.P. Morgan Healthcare Conference in San Francisco, California at 9:00 a.m. PT. Mr. Joyce will communicate that Danaher's fourth quarter 2017 adjusted diluted net earnings per share and core revenue growth are both expected to be above the high-end of the Company's previously announced guidance ranges. As previously announced, Danaher will hold its quarterly earnings conference call for the fourth quarter and year-end 2017 on Tuesday, January 30, 2018 at 8:00 a.m. ET.
Also on Market Tamer…
Follow Us on Facebook